Q1 2020 Editas Medicine Inc Earnings Call
Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.
Editas Medicine (EDIT) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
AGN-151587 (EDIT-101) is the first in vivo CRISPR medicine to be administered to patients Additional patient enrollment to the BRILLIANCE Clinical Trial is ongoing DUBLIN,.
It's been a pretty great week for Editas Medicine, Inc. (NASDAQ:EDIT) shareholders, with its shares surging 11% to...
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced results from a pre-clinical study evaluating multi-gene knockout and transgene knock-in using its proprietary engineered CRISPR-Cas12a (EngCas12a) in induced pluripotent stem cells (iPSCs) for the development of engineered cell immunotherapy medicines. The results of this study further reinforce Editas Medicine’s belief in the transformative potential of iPSC-derived natural killer (iNK) cells as off-the-shelf engineered cell medicines for the treatment of solid tumor cancers.
Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the initiation of IND-enabling activities for EDIT-201, an allogeneic natural killer (NK) cell medicine for the treatment of solid tumor cancers. “We have made significant progress in our HDNK (healthy-donor NK) cell medicine program, and we are excited to advance EDIT-201 into development for the treatment of solid tumors,” said Charles Albright, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine.
Editas Medicine, Inc. (EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2020. “The COVID-19 pandemic has given rise to unprecedented circumstances for Editas and the broader life sciences community,” said Cynthia Collins, Chief Executive Officer of Editas Medicine.
CAMBRIDGE, Mass., April 30, 2020 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on.
Image source: The Motley Fool. Editas Medicine, Inc. (NASDAQ: EDIT)Q1 2020 Earnings CallMay 7, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning.
Editas (EDIT) delivered earnings and revenue surprises of 11.54% and -3.82%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
With all the attention that COVID-19-related companies have gotten over the past couple of months, it's easy to forget that there are plenty of other promising stocks out there to invest in. While there are other insulin pump makers on the market, such as Tandem Diabetes, Insulet's OmniPod stands out for a couple of reasons.
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Company shares up substantially since early February IPO Continue reading...
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas (EDIT) beats on earnings in the first quarter of 2020 while revenues slightly miss estimates.
Q4 2019 Editas Medicine Inc Earnings Call
Editas has more favorable terms for its collaborations with big pharma companies, but it still has a long way to go.